Blood test for CD25 in scleroderma patients with lung disease
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Lungs & breathing clinical trials.
This study looks at the level of a protein called CD25 in your blood to see if it relates to lung problems (interstitial lung disease) in people with scleroderma. It may help doctors better understand and monitor this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of systemic sclerosis (scleroderma), based on standard medical criteria.
- You are 18 years or older.
- You do not have any other autoimmune disease (like lupus or rheumatoid arthritis).
- If you have lung scarring (interstitial lung disease), it must be caused by scleroderma, not by something else.
- You are willing to take part in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tiny particles in your blood to see if they can predict whether you might develop a serious lung condition called pulmonary arterial hypertension (high blood pressure in the lungs). It aims to find better ways to detect and manage this complication early.
This study helps doctors identify early signs of lung scarring (fibrosis) in patients with autoimmune diseases like scleroderma, rheumatoid arthritis, and Sjögren's syndrome. By catching this early, researchers hope to better understand and treat these complications.
This study tests a new way to find early signs of lung scarring (interstitial lung disease) in people with rheumatoid arthritis or scleroderma using a blood test and a lung ultrasound. It may help detect lung problems earlier, when treatment could be more effective.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This study tests a new way to help doctors spot early signs of lung disease in people with rheumatoid arthritis or scleroderma. It uses a computer tool during regular visits to ask about symptoms and decide if a lung test is needed.
This study looks at using chest CT scans to help predict how lung disease from scleroderma (SSc-ILD) may progress. It may help doctors better understand your condition.
Hear when a new Assessment of Serum Level of SCD25 in RA, SSc (with or Without ILD) and IPF and Its Correlation with Disease Activity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.